Lexeo Therapeutics officer plans $4.19K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Lexeo Therapeutics, Inc. officer Jose Manuel Otero is named in a notice covering the sale of 1,285 common shares, with an aggregate market value of $4,192.19 and an approximate sale date of November 17, 2026. Otero acquired the shares from the issuer through restricted stock vesting on November 16, 2026, as compensation.
The notice lists a prior sale of 1,304 common shares on August 18, 2026, for gross proceeds of $6,464.05. Its remarks state that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Key Figures
Key Terms
Restricted Stock Vesting financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.